Duration of blood-pressure benefit from stem-cell infusion typically extends 6–18 months, with best outcomes observed when patients maintain lifestyle modification and continue at least low-dose antihypertensive therapy. Some patients experience gradual blood-pressure increase over 12–24 months, potentially requiring booster infusions or medication escalation. Durability depends on baseline endothelial reserve and ongoing cardiovascular risk-factor control (smoking, diet, exercise). Long-term freedom from antihypertensive drugs beyond 2 years post-infusion is rarely documented. Benefit often plateaus; MSCs may enhance rather than replace pharmacotherapy.
Arterial hypertension, or high blood pressure, arises from dysregulated vascular tone, altered endothelial function, sympathetic overactivity, and rarefaction of capillary beds — pathophysiological mechanisms studied across essential and secondary forms. Stem-cell research investigates whether placental mesenchymal stem cells and exosome preparations can restore endothelial homeostasis, promote vascular regeneration, suppress renin-angiotensin-aldosterone axis overactivity, and enhance nitric-oxide bioavailability. With 35 registered trials and 4 currently recruiting, the therapeutic rationale targets restoration of vascular biology rather than symptomatic blood-pressure control. Early clinical data suggest potential for reducing office and ambulatory blood pressure, improving microvascular function, and reducing left-ventricular hypertrophy when administered as adjuncts to standard antihypertensive therapy.
我是候选人吗？ → · Arterial Hypertension: full overview → · 动脉高血压成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估